[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374548":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":49,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Children's Hospital of Philadelphia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RH genotype matched red cell transfusions","EXPERIMENTAL","Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.",[13],"Biological: Red cell units that are genotype matched at the RHD and RHCE loci",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Red cell units that are genotype matched at the RHD and RHCE loci","Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Stella Chou, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","215-590-0947","chous@chop.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-75.16362,39.95238,{"lat":42,"lon":41},[45,46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[50,52],{"name":51,"class":6},"New York Blood Center",{"name":53,"class":54},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100374548","phase-1-rh-genotype-matched-rbc-transfusions-100374548",false,"NCT04156893","RH Genotype Matched RBC Transfusions","RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease","RBC","Inclusion Criteria:\n\n* Subjects age \\>6 months\n* Diagnosis of SCD, all genotypes\n* Require a period of chronic red cell transfusion therapy\n* Subject\u002Fparental\u002Fguardian permission (informed consent) and if appropriate, child assent\n\nExclusion Criteria:\n\n* Rare RH genotype that would preclude identification of sufficient RBC units\n* Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units\n* Alloimmunized to D antigen\n* Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols\n* Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures","ALL","6 Months",{"count":66,"type":67},35,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.",[74],"Sickle Cells Disease",[76],"Chronic Transfusion","2026-04-24",{"date":79,"type":80},"2026-04-27","ACTUAL",{"date":82,"type":80},"2020-01-30",{"date":84,"type":67},"2029-10",{"name":5,"class":6},1]